Drug Profile
Research programme: epilepsy seizure therapy - AbbVie
Alternative Names: GABA agonist for epilepsy seizure interventionLatest Information Update: 18 May 2020
Price :
$50
*
At a glance
- Originator MAP Pharmaceuticals
- Developer AbbVie
- Class
- Mechanism of Action GABA receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Seizures
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 16 Jul 2016 No recent reports of development identified for preclinical development in Seizures in USA (Inhalation, Inhalant)
- 01 Mar 2013 MAP Pharmaceuticals has been acquired by Allergan